GLP-1 Drug Interactions: Provider Quick Reference for Polypharmacy Management
Comprehensive drug interaction reference for GLP-1 medications covering absorption effects, narrow therapeutic index drugs, diabetes medications, psychiatric medications, and cardiovascular agents.
More on Provider-Facing
Clinical Reference
GLP-1 medications have no significant CYP450 interactions. Primary interaction mechanism is delayed gastric emptying affecting oral medication absorption. Focus monitoring on narrow therapeutic index drugs and medications where absorption timing is critical.
Drug Interaction Quick Reference
| Drug | Risk | Mechanism | Action |
|---|---|---|---|
| Lithium | High | Dehydration from GI SE elevates lithium levels | Check levels q2-4wk during titration. Aggressive hydration. |
| Warfarin | Moderate | Delayed absorption may alter INR timing | Check INR within 1-2 weeks of GLP-1 initiation. Monitor closely. |
| Levothyroxine | Low-Mod | Delayed absorption may reduce T4 levels | Check TSH at 6-8 weeks. Take on empty stomach consistently. |
| Oral Contraceptives | Low-Mod | Delayed absorption may reduce efficacy | Consider backup method during initial titration. Monitor breakthrough bleeding. |
| Insulin | High | Combined hypoglycemia risk | Reduce insulin 20-30% at GLP-1 initiation. Monitor BG closely. |
| Sulfonylureas | High | Combined hypoglycemia risk | Reduce sulfonylurea 50% at GLP-1 initiation. Consider discontinuation. |
| Digoxin | Moderate | Narrow TI, absorption may vary | Check digoxin level at 2-4 weeks. Monitor for toxicity signs. |
| Acetaminophen | Low | Delayed Tmax but same total absorption | Clinical significance minimal. No action needed. |
Clinical Pearls
Key Points
- No CYP450 interactions -- metabolic drug interactions unlikely
- Delayed absorption changes Tmax but usually not AUC
- Weight loss itself changes drug pharmacokinetics
- Most interactions are manageable with monitoring
High-Alert Situations
- Lithium + GLP-1: dehydration can be life-threatening
- Insulin + GLP-1: proactively reduce insulin dose
- Immunosuppressants: monitor trough levels closely
- Anticoagulants: increase INR monitoring frequency
Clinical Disclaimer: This reference is for licensed healthcare providers. Verify current interaction databases for complete information. Clinical judgment should guide individual patient management.
Frequently Asked Questions
What is the primary interaction mechanism for GLP-1 agonists?
The primary interaction mechanism is delayed gastric emptying, which can slow absorption of co-administered oral medications. This is most clinically significant for drugs with narrow therapeutic indices, time-sensitive dosing, or pH-dependent absorption. No significant CYP450 interactions have been identified for semaglutide or tirzepatide.
Which medications require closest monitoring with GLP-1?
Highest priority: lithium (dehydration risk elevates levels), warfarin (monitor INR more frequently), oral contraceptives (absorption may vary), levothyroxine (absorption timing), narrow-therapeutic-index drugs (digoxin, phenytoin, cyclosporine), and insulin/sulfonylureas (hypoglycemia risk).
Do GLP-1 medications affect CYP450 enzymes?
Semaglutide and tirzepatide have no clinically significant CYP450 interactions. They are not inducers or inhibitors of major CYP enzymes. The primary interaction concern is mechanical (delayed gastric emptying) rather than metabolic.
How should I counsel patients about timing oral medications?
For medications requiring consistent absorption: take on empty stomach 30-60 minutes before meals, or at bedtime when GI motility is less affected. For levothyroxine: maintain standard 30-60 minute fasting after dose. For oral contraceptives: consider non-oral methods or backup contraception during initial GLP-1 titration.
Trimi Provider Support
Compounded semaglutide from $99/mo or tirzepatide from $125/mo.
View Treatment OptionsMedical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication or treatment program.
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).